Document is current
Any future updates will be listed below
-
Authors
Offenhäuser, Carolin https://orcid.org/0000-0003-2518-1779
Dave, Keyur A.
Beckett, Kirrilee J.
Smith, Fiona M.
Jayakody, Buddhika A.
Cooper, Leanne T.
Agyei-Yeboah, Helen
McCarron, Jennifer K.
Li, Yuchen https://orcid.org/0000-0001-7091-3073
Bastick, Kate
Al-Ejeh, Fares https://orcid.org/0000-0002-1553-0077
Cullen, Jason K.
Coulthard, Mark G.
Gorman, Jeffrey J.
Boyd, Andrew W.
Day, Bryan W.
- License Information
-
More Information
Article History
Received: 2 August 2023
Revised: 9 October 2024
Accepted: 22 October 2024
First Online: 7 November 2024
Competing interests
: Provisional patent applications claiming the anti-EphA2 monoclonal antibodies 1F7 and 4B3 that are described in this manuscript have been filed by the QIMR Berghofer Medical Research Institute.
: All methods were performed in accordance with the relevant guidelines and regulations. All experimental protocols for the animal studies were approved by the QIMR Berghofer Animal Ethics Committee (Approval number: A0304-620M). The primary human glioblastoma cell lines WK1 and MN1 were generated in-house and have been reported previously [, ]. Patient tumor tissues to generate these cell lines were collected following informed consent and with approval from the Royal Brisbane Women’s Hospital and QIMR Berghofer Human Research Ethics Committees (Approval number: P3420, HREC/17/QRBW/577 Novel Therapies for Brain Cancer).
